Trial Profile
Two-years Follow-up of Melanoma Patients Treated by Nivolumab During the French ATU Program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Post-ATU
- 13 Sep 2021 Status changed from recruiting to completed.
- 05 Jun 2018 Results (n=342) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 01 Nov 2017 New trial record